IDEAYA Biosciences, Inc.
Close on Oct 19, 2026
- Market cap
- $3.11B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 3, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 4, 2026 | Before market open | $8.90M | $-1.22 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 5, 2026 | Before market open | $6.60M | $-1.11 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 17, 2026 | Before market open | $10.90M | $-0.94 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 4, 2025 | Before market open | $207.80M | $1.33 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | Before market open | – | $-0.88 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 13, 2025 | Before market open | $7.00M | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 4, 2024 | Before market open | – | $-0.60 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | Before market open | – | $-0.68 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 20, 2024 | Before market open | – | – | – |
Press releases
Announcements IDEAYA Biosciences filed with the SEC
IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Investigator’s Choice as First-Line Treatment for Patients with HLA-A2 Negative Metastatic Uveal Melanoma: Primary Results from the OptimUM-02 Trial Marlana Orloff,1 Egle Ramelyte,2 Marcus O. Butler,3 Piotr Rutkowski,4 Lorenza Di Guardo,5
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Precision Medicines JPM 2026 | 44th Annual Healthcare Conference January 2026 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
IDEAYA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023
Results of operations · EX-99.1 to Form 8-K
IDEAYA Biosciences, Inc. Reports Third Quarter 2023
Results of operations · EX-99.1 to Form 8-K
IDEAYA Biosciences, Inc. Reports Second Quarter 2023
Results of operations · EX-99.1 to Form 8-K
IDEAYA Biosciences, Inc. Reports First Quarter 2023 Financial Results
Results of operations · EX-99 to Form 8-K
IDEAYA Biosciences, Inc. Reports 2022 Financial Results
Results of operations · EX-99 to Form 8-K
IDEAYA Biosciences, Inc. Reports Third Quarter 2022
Results of operations · EX-99.1 to Form 8-K
IDEAYA Biosciences, Inc. Reports Second Quarter 2022
Results of operations · EX-99.1 to Form 8-K
IDEAYA Biosciences, Inc. Reports First Quarter 2022
Results of operations · EX-99.1 to Form 8-K
IDEAYA Biosciences, Inc. Reports 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K
IDEAYA Biosciences, Inc. Reports Third Quarter 2021
Results of operations · EX-99.1 to Form 8-K